AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that entered public markets through a de-SPAC business combination with Priveterra Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 with Priveterra Holdings LLC serving as sponsor. The company is focused on developing botulinum neurotoxin therapeutics targeting neurological and urological indications. On July 8, 2026, AEON filed an S-1 registration statement with the SEC under accession number 0001104659-26-081860, continuing its post-merger capital markets activity in the healthcare and biopharmaceutical sector. For full filing history, sponsor details, and deal-level analytics on AEON and hundreds of other SPAC transactions, sign up for complete data on SpacDesk.